Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 5/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616784 | 0.82 | SLC29A1 (0.48) | NPSR1MTORMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19949022 | 0.82 | CCNA2 (0.41) | ALDH1A1KDM4EHPGDNPSR1HSD17B10 | |
| SCHEMBL22440346 | 0.81 | MTOR (0.40) | ALDH1A1KDM4EHPGDNPSR1HSD17B10 | |
| SCHEMBL25021553 | 0.75 | HTR2C (0.49) | ALDH1A1KDM4EMTORADRB1HTR2C | |
| SCHEMBL19948171 | 0.75 | KRAS (0.36) | MTOR | |
| SCHEMBL19948563 | 0.75 | KRAS (0.36) | MTOR | |
| SCHEMBL30007840 | 0.75 | PARP1 (0.35) | — | |
| SCHEMBL19637840 | 0.75 | PARP1 (0.35) | — | |
| SCHEMBL19617060 | 0.75 | PARP1 (0.35) | — | |
| SCHEMBL28500547 | 0.73 | IDH1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3370/4885KDM4E 3689/4885HPGD 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.